CSL Limited retains rights to clazakizumab in end-stage kidney disease. Eli Lilly gets rights to the the IL-6-blocking antibody in other indications that could put it in competition with Novo Nordisk and Novartis.
Elli Lilly has been in the news lately because of the announced $1 billion investment in a joint innovation lab with Nvidia, an AI powerhouse player. But AI drug discovery is only part of the story of where AI can be leveraged in biopharma.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by AstraZeneca, AbbVie, Gilead Sciences, and Bristol Myers Squibb.
Jensen Huang, CEO of Nvidia and David Ricks, CEO of Eli Lilly, discussed their recently-announced partnership and the potential of GLP-1s at an event in San Francisco.
This year's J.P. Morgan Healthcare Conference brought a slew of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for six of the event’s most notable announcements.
Eliav Barr gave kudos to Eli Lilly for testing the company's Zepbound weight loss drug in combination with a psoriatic arthritis drug to achieve better results for the underlying inflammation.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity.
Nvidia has quietly become one of the most influential players in healthcare technology by supplying the accelerated computing and AI infrastructure that powers everything from imaging to drug discovery. The company’s restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the indispensable backbone of the healthcare industry’s AI transformation.
The high dose of Eli Lilly’s retatrutide led to an average 28.7% loss in body weight measured at 68 weeks. These Phase 3 results are the first from the experimental obesity drug’s broad clinical trial program, which is on track to yield seven data readouts in the coming year.
Eli Lilly is paying $75 million up front for global rights to AAV-AIPL1, a gene therapy on track for U.S. and European regulatory submissions in the rare, inherited eye disorder Leber congenital amaurosis 4, or LCA4. The deal brings to Lilly another late-stage gene therapy for the eyes following the pharma giant’s October acquisition of Adverum Biotechnologies and its lead program for wet AMD.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
October has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Eli Lilly, CommonSpirit Health and HLM Venture Partners welcomed new executives. There were also layoffs at organizations including Genentech and Jefferson Health.
Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis.
Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has clinical and regulatory validation from the recent FDA approval of Vertex Pharmaceuticals’ pain drug, Journavx.
Eli Lilly reported that in addition to achieving greater reductions in weight, Zepbound-treated patients achieved greater reductions in waist circumference compared to those treated with Novo Nordisk’s Wegovy. Full details from the head-to-head Phase 3 test were presented at the European Congress on Obesity meeting.
Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics.